• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PPD Earnings up 18% in Q4, Plans to Acquire AbCRO

PPD Earnings up 18% in Q4, Plans to Acquire AbCRO

February 10, 2009
CenterWatch Staff

Wilmington, N.C.-based CRO PPD reported full-year and fourth quarter 2008 earnings late yesterday, reflecting an 11% increase in its full year revenues despite a slight decrease in fourth quarter revenues.

Net income for the full year 2008 was $187.5 million, up from $163.4 in 2007. Net income for the quarter was also up—$47.2 million compared with a net income of $40.5 million in Q4 2007. Fourth quarter 2008 diluted earnings per share (EPS) were $0.40, an increase of 18% compared to $0.34 for the same period last year.

Net revenue for the fourth quarter 2008 was $368.2 million, down slightly from $375 million in the same period 2007. Net revenue for the full year 2008 was $1.57 billion, up from $1.41 billion in 2007.
PPD also announced yesterday its plans to acquire CRO AbCRO.

The acquisition, scheduled to be complete at the end of the first quarter 2009, is the second Central and Eastern Europe (CEE)-based acquisition for PPD, which acquired Russia-based CRO InnoPharma a year ago.

PPD has operations in Poland, Russia and Ukraine, and, with the acquisition of AbCRO, will gain entry into Romania, Bulgaria, Serbia and Croatia. AbCRO, although American-owned, provides Phase II to IV clinical study services in CEE, operating offices in Bulgaria, Croatia, Poland, Romania, Russia, Serbia and Ukraine.

“This acquisition will strengthen our foothold in Central and Eastern Europe and enhance our ability to conduct global trials for our clients. We see many synergies with AbCRO and anticipate a relatively seamless integration, with many of the AbCRO employees already well-versed on basic PPD procedures and systems,” said PPD CEO Fred Eshelman in a company statement.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing